ArticleJournal of magnetic resonance imaging : JMRI2018
Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score.
Article in Journal of magnetic resonance imaging : JMRI, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Is radiomic MRI a feasible alternative to OncotypeDX® recurrence score testing? A systematic review and meta-analysis.BJS open · 2021Pooled it
- Can apparent diffusion coefficient (ADC) distinguish breast cancer from benign breast findings? A meta-analysis based on 13 847 lesions.BMC cancer · 2019Pooled it
- A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death.NPJ breast cancer · 2025Article
- Radiomics Analysis of Breast MRI to Predict Oncotype Dx Recurrence Score: Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Breast Imaging: Correlation Between Axillary Lymph Nodes Apparent Diffusion Coefficient and Pathological Lymphovascular Invasion in Patients With Invasive Breast Cancer.European journal of breast health · 2025Article
- Nomograms Integrating MRI-derived Apparent Diffusion Coefficient and Clinicopathologic Features for Prediction of Axillary Lymph Node Metastasis in Breast Cancer.Radiology. Imaging cancer · 2025Article
- Prediction of lymphovascular invasion in non-mass enhancement breast cancer using DCE-MRI and clinical-pathological features.Frontiers in oncology · 2025Article
- The impact of radiogenomics on breast cancer.American journal of cancer research · 2025Review
- Non-contrast Breast MR Imaging.Radiologic clinics of North America · 2024Review
- Radiogenomics: a key component of precision cancer medicine.British journal of cancer · 2023Review
- Article
- Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence ScoreDiagnostics (Basel, Switzerland) · 2022Article
- Early SUVQuantitative imaging in medicine and surgery · 2021Article
- [Diffusion-Weighted Imaging as a Stand-Alone Breast Imaging Modality].Taehan Yongsang Uihakhoe chi · 2021Review
- Article
- Differentiation of Breast Lesions and Distinguishing Their Histological Subtypes Using Diffusion-Weighted Imaging and ADC Values.Frontiers in oncology · 2020Article
- Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results.Breast cancer research : BCR · 2019Article
- Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.Journal of magnetic resonance imaging : JMRI · 2019Article
- Diffusion-weighted imaging of the breast: current status as an imaging biomarker and future role.BJR open · 2019Review
- Clinical role of breast MRI now and going forward.Clinical radiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo measure the apparent diffusion coefficient (ADC) values in estrogen receptor-positive (ER+) and axillary lymph node-negative (LN-) invasive breast cancer and investigate the correlation of ADC with Oncotype Dx test recurrence scores (ODxRS). MATERIALS AND
methodsThis was a Health Insurance Portability and Accountability Act (HIPAA)-compliant single-site retrospective study. Patients underwent preoperative 3.0T MRI scans with additional diffusion-weighted imaging sequential scans (b = 0, 600 and b = 0, 1000 s/mm
resultsInvasive breast cancers, when scored as low-risk by ODxRS, had significantly higher ADC values compared with intermediate/high-risk lesions for both ADC
conclusionPreliminary findings suggest that lesion ADC values correlate with recurrence risk likelihood stratified using ODxRS. Hence, ADC is a potential surrogate biomarker for tumor aggressiveness. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 5 J. Magn. Reson. Imaging 2018;47:401-409.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.